Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer

Fig. 2

Integrin αVβ3 contributes to acquired EGFR-TKI resistance in NSCLC. a Expression of integrins was determined by western blot analysis. b The sensitivity of PC9GR cells transfected with si-ITGAV or si-NC to gefitinib was determined by CCK-8 assays. c The sensitivity of PC9GR cells transfected with si-ITGB3 or si-NC to gefitinib was determined by CCK-8 assays. d Integrin αV expression was detected in seven tumour tissues from lung adenocarcinoma patients before and after EGFR-TKI resistance by IHC (*P < 0.05; **P < 0.01)

Back to article page